Specialised Therapeutics and DKSH Join Forces to Enhance Cancer Treatment Access in Vietnam

Specialised Therapeutics and DKSH Collaborate for Cancer Care



In a significant move to enhance the treatment landscape for cancer patients in Vietnam, Singapore-based Specialised Therapeutics (ST) has entered into a strategic partnership with DKSH. This collaboration aims to leverage DKSH's deep understanding of the local market while introducing innovative oncology therapies tailored to the needs of Vietnamese patients.

According to 2022 data from GLOBOCAN, Vietnam is facing a rising cancer incidence, with nearly 180,000 new cases diagnosed annually, and more than 120,000 deaths attributed to cancer each year. Breast cancer emerges as the most commonly diagnosed cancer among Vietnamese women, while lung cancer remains a top contributor to cancer-related mortality. This partnership will specifically address these pressing health issues.

Carlo Montagner, CEO of Specialised Therapeutics, emphasized the importance of selecting the right market partner. He stated, “Vietnam is a priority market for ST, and the right partner makes all the difference. DKSH brings deep local market knowledge and expertise, and we look forward to introducing several vital cancer medicines to patients in Vietnam over the next few years.” This strategic alignment is anticipated to propel ST’s initiative of introducing critical cancer medicines that can save lives and improve health outcomes for many.

Charaf Kadri, Vice President of Healthcare at DKSH, echoed Montagner's sentiments, underlining their commitment to enhancing healthcare access. He said, “We are proud to partner with Specialised Therapeutics to strengthen access to specialty oncology care in Vietnam. At DKSH, our commitment to 'Healthcare for All' drives everything we do. By combining ST's specialty oncology expertise with DKSH's local market knowledge and capabilities, we aim to help improve healthcare outcomes across Vietnam.”

This collaboration marks a significant step forward not only for Specialised Therapeutics but also for the healthcare ecosystem in Vietnam. ST has previously established its presence across Southeast Asia, Australia, and New Zealand, having obtained regulatory approvals in key markets including Australia, New Zealand, Singapore, Thailand, and Malaysia. The extension of their regional model into Vietnam signifies a growing emphasis on enhancing healthcare provisions in one of Southeast Asia's largest and rapidly expanding markets.

Specialised Therapeutics, founded in 2007, is dedicated to delivering breakthrough therapies and medical technologies to regions with significant healthcare needs. The company's operations span a variety of conditions, including oncology, hematology, neurology, and dermatology, and aim to fill gaps in medical treatment, particularly in underserved communities.

In addition to its pharmaceutical advancements, DKSH boasts over 160 years of experience in Market Expansion Services, concentrating on enhancing growth across Asia Pacific, Europe, and North America. With a mission to enrich lives, DKSH integrates sourcing, market access support, market insights, marketing and sales, logistics, and after-sales services into its healthcare framework. By establishing this partnership in Vietnam, both companies reaffirm their shared objective of driving improvements in healthcare access and outcomes for the populations they serve.

As they gear up for this ambitious collaboration, both Specialised Therapeutics and DKSH look forward to the forthcoming years filled with hope and innovation in the face of Vietnam's growing cancer burden. Now, the spotlight is on them to see how they will navigate the complexities of healthcare delivery to significantly impact the lives of many families and communities in Vietnam.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.